A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease
ConditionHuntington's Disease
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age25-70
SponsorAlnylam Pharmaceuticals
About this trial
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of single or repeat doses of ALN-HTT02.
Eligibility criteria
Qualifiers
Has stage 2 or early Stage 3 Huntington's disease (HD), per the Huntington's Disease Integrated Staging System (HD-ISS)
Disqualifiers
Has significant structural or degenerative neurologic disease other than Huntington's Disease (HD) at screening
Has primary or secondary immune compromise at screening due to infections, medical conditions, or chronic therapies
Has alanine aminotransferase or aspartate aminotransferase >2× upper limit of normal (ULN)
Has an estimated glomerular filtration rate (eGFR) of <60 mL/min/1.73m² at screening
Trial design
Treatments tested in this trial
- ALN-HTT02
- Placebo
Treatment groups
66 Participants
are divided into 2 treatment groupsLocations
19Canada
Clinical Trial SiteT6G 2B7, Edmonton Canada
Clinical Trial SiteH2W 1T8, Montreal Canada
Clinical Trial SiteK1Y4E9, Ottawa Canada
Clinical Trial SiteV6T 2B5, Vancouver Canada
Sponsors and collaborators
Alnylam Pharmaceuticals
Lead sponsor
Source ClinicalTrials.gov